Researchers Rewire CD19 to Overcome CAR-T Resistance in Soft Solid Tumors
Updated
Updated · Nature.com · Jul 6
Researchers Rewire CD19 to Overcome CAR-T Resistance in Soft Solid Tumors
3 articles · Updated · Nature.com · Jul 6
Summary
A Nature Biomedical Engineering study found cancer cells grown on soft matrices were less vulnerable to CAR-T killing, identifying a mechanical source of resistance in solid tumors.
Softness triggered sustained calcium activity and elevated extracellular ATP, and a doxycycline-gated mechano-recorder marked the cells that had sensed those cues over time.
Recorder-positive cells showed stem-like programs—including EMT, hypoxia responses, oncogenic signaling and higher stemness markers—across cell lines and patient-derived samples, linking softness to hard-to-kill cancer stem-like cells.
Replacing the recorder’s fluorescent output with CD19 turned that mechanosensing system into a mechano-reprogrammer, making softness-responsive cells recognizable to CD19-directed T cells.
In culture and mouse models, the rewired approach improved elimination of resistant cells, suggesting tumor mechanics can be converted from a barrier into a therapeutic target for solid-tumor CAR-T therapy.
CAR T-cell therapy has transformed blood cancer treatment, but its use in solid tumors faces major challenges. Solid tumors develop ways to evade therapy, such as releasing TGF-β to suppress immune responses and promote tumor growth. These defenses make immunotherapies less effective and can cause CAR-T cells to fail, sometimes due to senescence. To overcome this, new strategies are being developed that target both the tumor’s physical defenses and the immune environment, aiming to make solid tumors more vulnerable and improve the long-term success of CAR-T cell therapy.